Ocugen (NASDAQ:OCGN - Get Free Report) posted its earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01, Zacks reports. The business had revenue of $1.48 million for the quarter. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%.
Ocugen Stock Performance
Shares of Ocugen stock traded up $0.05 during trading hours on Friday, reaching $0.76. The company's stock had a trading volume of 8,329,945 shares, compared to its average volume of 4,466,749. Ocugen has a one year low of $0.52 and a one year high of $2.06. The company's 50 day simple moving average is $0.67 and its 200 day simple moving average is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The stock has a market cap of $221.94 million, a P/E ratio of -4.22 and a beta of 4.21.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price target on shares of Ocugen in a research report on Monday. HC Wainwright cut their price objective on Ocugen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Monday.
Read Our Latest Stock Report on Ocugen
Ocugen Company Profile
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Featured Stories
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
